Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) reached 70.41% versus a 1-year low price of $17.00. The stock was last seen 7.58% higher, reaching at $28.97 on 01/18/2018. At recent session, the prices were hovering between $26 and $29.4599. This company shares are 25.65% off its target price of $36.4 and the current market capitalization stands at $1B. The recent change has given its price a 13.11% lead over SMA 50 and -26.67% deficit over its 52-week high. The stock witnessed 30.03% gains, -9.67% declines and 17.1% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BHVN’s volatility during a week at 7.28% and during a month it has been found around 5.67%.Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Top Holders
Institutional investors currently hold around $440 million or 46% in BHVN stock. Look at its top three institutional owners. Ra Capital Management, Llc owns $53.79 million in Biohaven Pharmaceutical Holding Company Ltd., which represents roughly 5.38% of the company’s market cap and approximately 12.22% of the institutional ownership. Similar statistics are true for the second largest owner, Vivo Capital, Llc, which owns 1,976,818 shares of the stock are valued at $53.24 million. The third largest holder is Vhcp Management Ii, Llc, which currently holds $44.82 million worth of this stock and that ownership represents nearly 4.48% of its market capitalization.
At the end of 09/30/2017 reporting period, 51 institutional holders increased their position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) by some 2,403,822 shares, 26 decreased positions by 1,756,380 and 11 held positions by 12,168,893. That puts total institutional holdings at 16,329,095 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 477,026 shares while 12 institutional investors sold out their entire positions totaling 495,816 shares.Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Insider Trades
Multiple company employees have indulged in significant insider trading. Biohaven Pharmaceutical Holding Company Ltd. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Doogan Declan has sold 128,058 shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in trading session dated Jan. 18, 2018. These shares are worth $3,451,163 and were traded at $26.95 each. The SEC filing shows that Bailey Gregory performed a sale of 40,000 shares. The Director disposed these shares by way of transaction on Jan. 16, 2018. The company’s shares were given away at $26.52 per share worth to an income of some $1,060,800 on account of Bailey Gregory.
Director, Doogan Declan, sold 121,942 common shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in the open market. In a transaction dated Jan. 12, 2018, the shares were put up for sale at an average price of $26.78, raking in a sum of $3,265,607. After this sale, 1,178,058 common shares of BHVN are directly owned by the insider, with total stake valued at $34,128,340.
In the transaction dated Jan. 10, 2018, the great number of shares disposed came courtesy the Chief Medical Officer; Berman Robert disposed a total of 35,000 shares at an average price of $27.52, amounting to approximately $963,200. The insider now directly owns 1,070,050 shares worth $30,999,349.Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Analyst Guide
Several analysts have released their opinion on Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), with 4 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.25 average brokerage recommendation.